UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 17, 2021
Monterey Bio Acquisition Corporation
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation) | 001-40861
(Commission
File Number) | 85-2204842
(I.R.S. Employer
Identification No.) |
17 State Street 21st Floor New York, NY (Address of principal executive offices) | 10004 (Zip Code) |
(917) 267-0216
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
| Units, each consisting of one share of Common Stock and one redeemable Warrant | | MTRYU | | The Nasdaq Stock Market LLC |
| Common Stock, par value $0.0001 per share | | MTRY | | The Nasdaq Stock Market LLC |
| Redeemable Warrants, each Warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share | | MTYRW | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On November 17, 2021, Monterey Bio Acquisition Corporation (the “Company”) issued a press release, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K, announcing that the holders of the Company’s units (the “Units”) may elect to separately trade the shares of common stock and warrants included in the Units commencing on November 22, 2021. Those Units that are not separated will continue to trade on the Nasdaq Global Market (“Nasdaq”) under the symbol “MTRYU” and the shares of common stock and warrants that are separated will trade on Nasdaq under the symbols “MTRY” and “MTRYW,” respectively. Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the holders’ Units into shares of common stock and warrants.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | Monterey Bio Acquisition CorpORaTION |
| | |
| | By: | /s/ Sanjeev Satyal |
| | | Name: | Sanjeev Satyal |
| | | Title: | Chief Executive Officer |
Date: November 17, 2021
